Social outcomes good for most pediatric brain tumor survivors

October 21, 2012
Social outcomes good for most pediatric brain tumor survivors
While the majority of survivors of pediatric embryonal tumors display positive social outcomes several years after diagnosis and treatment, specific risk factors may affect social adjustment and behavior over the long term, according to research published online Oct. 15 in the Journal of Clinical Oncology.

(HealthDay)—While the majority of survivors of pediatric embryonal tumors display positive social outcomes several years after diagnosis and treatment, specific risk factors may affect social adjustment and behavior over the long term, according to research published online Oct. 15 in the Journal of Clinical Oncology.

Tara M. Brinkman, Ph.D., of the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues conducted a five-year, prospective, longitudinal study involving 220 survivors of pediatric embryonal tumors to evaluate social outcomes for these children.

The researchers found that, on measures of social functioning, few children were reported to have clinically elevated scores. Although the mean scores differed significantly from population norms, they were within the average range. Compared with patients with average-risk treatment status, children with high-risk treatment status were significantly more likely to have increased social problems and display withdrawn/depressed behavior. Over time, there were greater parent-reported social problems for those with posterior fossa syndrome. Compared with , females exhibited higher withdrawn/depressed scores over time. Parent report of social functioning also correlated with patient intelligence, age at diagnosis, and parent .

"Results of this study largely suggest positive social adjustment several years after diagnosis and treatment of a pediatric embryonal tumor," the authors write. "However, several factors, including treatment risk status and posterior fossa syndrome, may be important precursors of long-term social outcomes. Future research is needed to elucidate the trajectory of social functioning as these patients transition into adulthood."

Explore further: BMI and lean body mass decline after allogeneic HSCT

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

BMI and lean body mass decline after allogeneic HSCT

October 4, 2012
(HealthDay)—In survivors of childhood hematologic malignancies who have received allogeneic hematopoietic stem cell transplantation (alloHSCT), body mass index (BMI) decreases significantly, mainly due to a reduction in ...

Studies link depression, breast cancer outcomes

November 2, 2011
This year, more than 230,000 women will be diagnosed with breast cancer and nearly 40,000 women will not survive their battle with cancer, according to the American Cancer Society. New research from the University of Missouri ...

Health-related QoL evaluated for children with brain tumors

May 9, 2012
(HealthDay) -- In children and adolescents with brain tumors treated with proton radiation, health-related quality of life (HRQoL) scores are affected by both disease type and treatment, with assessments made by the patients ...

Six developmental trajectories ID'd in children with autism

April 2, 2012
(HealthDay) -- Six longitudinal developmental trajectories have been identified among children with autism, with significant heterogeneity seen in developmental pathways within these trajectories, according to a study published ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.